Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: Implications for "nMDA antagonist modelling" of schizophrenia

Psychopharmacology

Volumn 205, Issue 2, 2009, Pages 203-216

  Gilmour, Gary ^a   Pioli, Elsa Y ^a   Dix, Sophie L ^a   Smith, Janice W ^a   Conway, Michael W ^a   Jones, Wendy T ^a   Loomis, Sally ^a   Mason, Rebecca ^a   Shahabi, Shahram ^a   Tricklebank, Mark D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Instrumental conditioning; Ketamine; Motivation; NR2A; NR2B; PCP; Psychosis; Variable interval

Indexed keywords

[1 (4 BROMOPHENYL)ETHYLAMINO (2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YL)METHYL]PHOSPHONIC ACID; ALPHA AMINO 2' CHLORO 5 (PHOSPHONOMETHYL)[1,1' BIPHENYL] 3 PROPANOIC ACID; DIZOCILPINE; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NVPAAM 077; PHENCYCLIDINE; RO 256981; SDZ 220581; TRAXOPRODIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SELECTIVITY; HYPERACTIVITY; INSTRUMENTAL CONDITIONING; LOCOMOTION; MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SCHIZOPHRENIA; STIMULUS RESPONSE; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MOTOR ACTIVITY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; TIME FACTORS;

EID: 67649964302     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1530-7     Document Type: Article

References (48)

1. CM Adler AK Malhotra I Elman T Goldberg M Egan D Pickar A Breier 1999 Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia American Journal of Psychiatry 156 10 1646 1649 (Pubitemid 29460002)
2. NC Andreasen 1982 Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39 784 788 (Pubitemid 12090301)
3. YP Auberson H Allgeier S Bischoff K Lingenhoehl R Moretti M Schmutz 2002 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition Bioorg Med Chem Lett 12 1099 1102 (Pubitemid 34242811)
4. JC Badcock PT Michie L Johnson J Combrinck 2002 Acts of control in schizophrenia: dissociating the components of inhibition Psychol Med 32 287 297 (Pubitemid 34162587)
5. TA Bowdle AD Radant DS Cowley ED Kharasch RJ Strassman PP Roy-Byrne 1998 Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations Anesthesiology 88 82 88
6. S Castellani PM Adams 1981 Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats Eur J Pharmacol 73 143 154 (Pubitemid 11039752)
7. F Chaperon W Muller YP Auberson MD Tricklebank HC Neijt 2003 Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-d-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit Behavioural Pharmacology 14 5-6 477 87
8. PL Chazot 2000 CP-101606 Pfizer Inc Curr Opin Investig Drugs 1 370 374 (Pubitemid 30942853)
9. BL Chenard J Bordner TW Butler LK Chambers MA Collins DL De Costa MF Ducat ML Dumont CB Fox EE Mena 1995 (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-d-aspartate responses J Med Chem 38 3138 3145
10. JT Coyle G Tsai D Goff 2003 Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia Ann N Y Acad Sci 1003 318 327 (Pubitemid 38083065)
11. R Dingledine K Borges D Bowie SF Traynelis 1999 The glutamate receptor ion channels Pharmacol Rev 51 7 61 (Pubitemid 29113865)
12. EF Domino P Chodoff G Corssen 1965 Pharmacologic effects of CI-581, a new dissociative anesthetic, in man Clin Pharmacol Ther 6 279 291
13. MJ Dunn S Killcross 2007 Clozapine, SCH 23390 and alpha-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance Psychopharmacology (Berl) 190 403 414 (Pubitemid 46204458)
14. G Fischer V Mutel G Trube P Malherbe JN Kew E Mohacsi MP Heitz JA Kemp 1997 Ro 25-6981, a highly potent and selective blocker of N-methyl-d-aspartate receptors containing the NR2B subunit Characterization in vitro. J Pharmacol Exp Ther 283 1285 1292
15. PA Frizelle PE Chen DJ Wyllie 2006 Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2, 3-dioxo-1, 2, 3, 4-tetrahydroquino xalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-d-aspartate receptors: Implications for studies of synaptic transmission Mol Pharmacol 70 1022 1032 (Pubitemid 44268459)
16. JM Gold JA Waltz KJ Prentice SE Morris EA Heerey 2008 Reward processing in schizophrenia: a deficit in the representation of value Schizophr Bull 34 835 847
17. RJ Herrnstein 1970 On the law of effect J Exp Anal Behav 13 243 266
18. GA Higgins TM Ballard M Enderlin M Haman JA Kemp 2005 Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat Psychopharmacology (Berl) 179 85 98 (Pubitemid 40576695)
19. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. [Review] [189 refs]. Molecular Psychiatry 9(11):984-97, 979
20. DC Javitt SR Zukin 1991 Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1301 1308
21. J Jensen M Willeit RB Zipursky I Savina AJ Smith M Menon AP Crawley S Kapur 2008 The formation of abnormal associations in schizophrenia: neural and behavioral evidence Neuropsychopharmacology 33 473 479
22. JD Jentsch RH Roth 1999 The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 201 225 (Pubitemid 29067401)
23. JW Johnson SE Kotermanski 2006 Mechanism of action of memantine Curr Opin Pharmacol 6 61 67 (Pubitemid 43103820)
24. S Kapur D Mamo 2003 Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog Neuropsychopharmacol Biol Psychiatry 27 1081 1090 (Pubitemid 37464954)
25. B Kirkpatrick WS Fenton WT Carpenter Jr SR Marder 2006 The NIMH-MATRICS consensus statement on negative symptoms Schizophr Bull 32 214 219
26. JH Krystal LP Karper JP Seibyl GK Freeman R Delaney JD Bremner GR Heninger MB Bowers Jr DS Charney 1994 Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Archives of General Psychiatry 51 3 199 214 (Pubitemid 24081509)
27. MR Lofwall RR Griffiths MZ Mintzer 2006 Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults Exp Clin Psychopharmacol 14 439 449 (Pubitemid 44789965)
28. ED Luby BD Cohen G Rosembaum JS Gottlieb R Kelley 1959 Study of a new schizophrenomimetic drug; sernyl AMA Arch Neurol Psychiatry 81 363 369
29. DR Lynch RP Guttmann 2001 NMDA receptor pharmacology: perspectives from molecular biology Curr Drug Targets 2 215 231 (Pubitemid 32821467)
30. JS MacDonall 2005 Earning and obtaining reinforcers under concurrent interval scheduling J Exp Anal Behav 84 167 183 (Pubitemid 41452635)
31. AK Malhotra DA Pinals H Weingartner K Sirocco CD Missar D Pickar A Breier 1996 NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 5 301 307 (Pubitemid 26151927)
32. F Menniti B Chenard M Collins M Ducat I Shalaby F White 1997 CP-101, 606, a potent neuroprotectant selective for forebrain neurons Eur J Pharmacol 331 117 126 (Pubitemid 27331439)
33. J Micallef S Tardieu S Gentile E Fakra E Jouve R Sambuc O Blin 2003 Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects Neurophysiol Clin 33 138 147 (Pubitemid 36994462)
34. F Murray J Kennedy PH Hutson J Elliot I Huscroft K Mohnen MG Russell S Grimwood 2000 Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro Eur J Pharmacol 397 263 270 (Pubitemid 30323777)
35. V Mutel D Buchy A Klingelschmidt J Messer Z Bleuel JA Kemp JG Richards 1998 In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits J Neurochem 70 2147 2155 (Pubitemid 28207840)
36. T Nabeshima H Fukaya K Yamaguchi K Ishikawa H Furukawa T Kameyama 1987 Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine Eur J Pharmacol 135 23 33 (Pubitemid 17051006)
37. S Nakanishi 1992 Molecular diversity of glutamate receptors and implications for brain function Science 258 597 603
38. JW Newcomer NB Farber V Jevtovic-Todorovic G Selke AK Melson T Hershey S Craft JW Olney 1999 Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 106 118 (Pubitemid 29010370)
39. KL Nicholson RS Mansbach FS Menniti RL Balster 2007 The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-d-aspartate antagonist CP-101 606 in rats and rhesus monkeys Behav Pharmacol 18 731 743 (Pubitemid 350076430)
40. T Passie M Karst B Wiese HM Emrich U Schneider 2005 Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man Neuropsychobiology 51 226 233 (Pubitemid 40976405)
41. DJ Sanger A Jackson 1989 Effects of phencyclidine and other N-methyl-d-aspartate antagonists on the schedule-controlled behavior of rats J Pharmacol Exp Ther 248 1215 1221 (Pubitemid 19100775)
42. RC Smith C Biggs G Vroulis S Brinkman 1981 Effects of chronic administration of phencyclidine on stereotyped and ataxic behaviors in the rat Life Sci 28 1163 1174 (Pubitemid 11100486)
43. FA Stephenson 2001 Subunit characterization of NMDA receptors Curr Drug Targets 2 233 239 (Pubitemid 32821468)
44. S Urwyler D Laurie DA Lowe CL Meier W Muller 1996 Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-d-aspartate receptor antagonist-I. Pharmacological characterization in vitro Neuropharmacology 35 643 654 (Pubitemid 26308541)
45. CX Wang A Shuaib 2005 NMDA/NR2B selective antagonists in the treatment of ischemic brain injury Curr Drug Targets CNS Neurol Disord 4 143 151 (Pubitemid 40612988)
46. XM Wang SB Bausch 2004 Effects of distinct classes of N-methyl-d-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists Neuropharmacology 47 7 1008 1020 (Pubitemid 39535841)
47. A Wenzel L Scheurer R Kunzi JM Fritschy H Mohler D Benke 1995 Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain Neuroreport 7 45 48 (Pubitemid 26077198)
48. X Xu EF Domino 1994 Asymmetric cross-sensitization to the locomotor stimulant effects of phencyclidine and MK-801 Neurochem Int 25 155 159 (Pubitemid 24273631)